Grufity logo
Grufity logo
LIPO

LIPO - Lipella Pharmaceuticals Inc. Stock Price, Fair Value and News

$0.10+0.02 (+25.00%)
Market Closed as of 15 Jun 2026, 04:00 pm ET

79/100

LIPO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

79/100

LIPO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LIPO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIPO Price Action

Last 7 days

-20%

Last 30 days

100%

Last 90 days

-52.9%

Trailing 12 Months

-97.0%

LIPO RSI Chart

LIPO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIPO Valuation

Market Cap

369.7K

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.79

EV/EBITDA

0.28

Price/Free Cashflow

-0.08

LIPO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LIPO Fundamentals

LIPO Revenue

Revenue (TTM)

470.2K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

LIPO Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

13.19%

Earnings Growth (Qtr)

5.53%

LIPO Profitability

EBT Margin

-1133.60%

Return on Equity

-358.28%

Return on Assets

-226.82%

Free Cashflow Yield

-1.3K%

LIPO Investor Care

Shares Dilution (1Y)

364.76%

Diluted EPS (TTM)

-2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025519.9K470.2K--
2024477.4K507.2K483.5K536.4K
2023250.5K316.9K383.3K449.6K
2022221.8K--184.2K
2021---259.3K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Lipella Pharmaceuticals Inc.

LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
 CEO
 WEBSITElipella.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

Lipella Pharmaceuticals Inc. Frequently Asked Questions

LIPO is the stock ticker symbol of Lipella Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Lipella Pharmaceuticals Inc. is 369.67 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, LIPO's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIPO PE ratio will change depending on the future growth rate expectations of investors.